HKEX: 1177
Monthly return of equity issuer on movements in securities for the month ended 30 september 2026
View original source (HKEXnews)
Earlier from Sino Biopharmaceutical
- Voluntary announcement - enter into strategic biosimilars partnership with stada
- Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
- Sino Biopharmaceutical: Once-Yearly Dosing, Targeting Cardiovascular Disorders, First US Patient Enrolled in China-US Phase II Clinical Trial of Hygieia's Kylo-11
- Sino Biopharm Releases 2025 Annual Results: Revenue and Net Profit Maintain Double-Digit Growth, Innovative Product Revenue Exceeds RMB 15 Billion